ROLE OF GENETIC ALTERATIONS IN BREAST CANCER PROGRESSION.
DOI:
https://doi.org/10.53555/eijbps.v11i1.61Keywords:
Early breast cancer, The beta-catenin gene, The winglees-related integration site (wnt)) singnalling pathway, The HCCRI (Human Cervical cancer Related 1) gene, The TIMP2 (Tissue Inhibitor of Metalloproteinases 2) gene.Abstract
Breast cancer is a multifactorial disease and represents the tumor formation through non-controlled cellular proliferation in the breast tissue. To understand the concept of breast cancer, one has to study the types, risk factors, diagnosis, treatment and latest research about the disease[1].While breast cancer remains a premier health concern, the advances made in research methods and tools, early detection and treatments have dramatically improved survival rates and quality of life for many patients [2].The incidence rates for breast cancer have been on the increase due to increased awareness, better diagnostic facilities and changes in lifestyle[3].The Wnt signaling pathway normally plays a very fundamental role in cell growth, differentiation and embryonic development. Understanding this pathway is important for the development of targeted therapies and advanced understanding in the advancement of regenerative medicine[4].HCCRI is an abbreviation of Human Cervical cancer Related 1, a gene implicated in the development of cancer especially in cervical cancer. It encodes for a protein involved in regulating all proliferation and apoptosis. Overexpression of HCCRI has been implicated in tumor progressions and prognosis in various cancers. Research indicates that HCCRI could be utilized as a biomarker for diagnosis in cancer and prognosis while the targeting of HCCRI can offer new therapeutic strategies in managing cancer[5].The TIMP2 gene encodes a tissue inhibitor of metalloproteinases 2-a protein that plays a critical role in regulating extracellular matrix remodeling through the inhibition of matrix metalloproteinases. This inhibition controls the degradation and remodeling of tissue leading to various physiological processes such as wound healing and embryogenesis. TIMP2 is involved in maintaining tissue integrity and has been implicated in various pathological conditions including cancer metastasis and cardiovascular diseases. It operates by binding to MMPs, thus preventing their activity and subsequent breakdown of extracellular characterized by excessive tissue remodelling or insufficient tissue repair[6].
References
Perou, C. M., et al. (2000). "Molecular portraits of human breast tumors." Nature, 406(6797), 747-752.
Schmid, P., et al. (2018). "Pembrolizumab for early triple-negative breast cancer." Nature Reviews Clinical Oncology, 15(12), 728-740.
Gradishar, W. J., et al. (2016). "Breast Cancer." New England Journal of Medicine, 375(17), 1592-1604.
Clevers, H. (2012). "Wnt/β-Catenin Signaling in Development and Disease." Cell, 149(6), 1192-1205.
Nusse, R., & Clevers, H. (2017). "Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutics." Cell, 169(6), 985-999.
Gonzalez, E. M., et al. (2014). "HCCR1: A New Oncogene in Cancer." Molecular and Cellular Biology, 34(18), 3447-3460.
Baker, A. H., et al. (2018). "Tissue inhibitors of metalloproteinases: Biological actions and therapeutic opportunities." Nature Reviews Drug Discovery, 17(8), 624-645.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018).
Miki, Y., Swensen, J., Shattuck-Eidens, D., et al. (1994).
Hormonal Therapy in Breast Cancer: Current Perspectives and Future Directions"
Endocrine Reviews, 2023.
(Kelsey, J. L., Gammon, M. D., & John, E. M. (1993). "Reproductive factors and breast cancer." Epidemiologic Reviews, 15(1), 36-47.
Veronesi, U., Cascinelli, N., Mariani, L., et al. (2002).
Microbiome and Breast Cancer: The Link Between Gut Health and Cancer Outcomes"Nature Communications, 2023.
Emerging Therapeutic Targets in Breast Cancer" Nature Reviews Clinical Oncology, 2023
Clevers, H. (2012). "Wnt/β-Catenin Signaling in Development and Disease." Cell, 149(6), 1192-1205.
Chlebowski, R. T., & Schwartz, P. E. (2005). "Nutrition and physical activity in the prevention of breast cancer."
Nusse, R., & Varmus, H. (2012). "Wnt genes." Cell, 149(6), 1246-1260.
Clevers, H. (2006). "Wnt/β-catenin signaling in development and disease." Cell, 127(3), 469-480.
Barker, N., & Clevers, H. (2006). "Tracking down the Wnt pathway in cancer." Cell, 125(3), 497-500.
Kawamura, Y., & Matsuura, K. (2018). "Wnt signaling in vertebrate development." Nature Reviews Molecular Cell Biology, 19(12), 740-757.
Bai, L., et al. (2019). "The Wnt/β-catenin pathway in breast cancer: a comprehensive review." Cancer Management and Research, 11, 1579-1589.
Jung, H., et al. (2019) "Wnt/β-catenin signaling in breast cancer: implications for therapy." Breast Cancer Research and Treatment, 175(3), 659-670.
Saha, S., & Lu, Z. (2018). "The Wnt signaling pathway in breast cancer: the stem cell perspective." Cancer Stem Cells in Breast Cancer, 213-227.
Roh, M. H., et al. (2020). "The Wnt/β-catenin signaling pathway as a therapeutic target in breast cancer." Cancers, 12(10), 2761.
O'Shaughnessy, J. (2013). "Extending survival with chemotherapy in metastatic breast cancer." The New England Journal of Medicine, 369(20), 1955-1963.
Louro, I.D., et al. "Breast Cancer Biomarkers: An Old Story with a New End." Genes, 2023
Lee, J., et al. "The HCCR Oncoprotein as a Biomarker for Human Breast Cancer." Clinical Cancer Research, 2005
Graham, T. A., & R. L. McCulloch (2013). "The impact of clonal evolution on tumor heterogeneity." Nature Reviews Cancer, 13(8), 535-548.
Gennari, A., et al. "ESMO Clinical Practice Guideline for the Diagnosis, Staging, and Treatment of Patients with Metastatic Breast Cancer." Annals of Oncology, 2021
Gonzalez, E., et al. (2014). "The role of HCCR1 in breast cancer: its potential as a biomarker for early detection." International Journal of Cancer, 134(8), 1833-1844.
Howlader, N., et al. "US Incidence of Breast Cancer Subtypes Defined by Hormone Receptor and HER2 Status." Journal of the National Cancer Institute, 2014
Liu, C., et al. (2022). "HCCR1 modulates immune responses in breast cancer by regulating T cell activity." Cancer Immunology, Immunotherapy, 71(3), 485-496.
Mateo, J., et al. "A Framework to Rank Genomic Alterations as Targets for Cancer Precision Medicine." Annals of Oncology, 2018
Nishida, N., et al. (2018). "Human cervical cancer resistance protein 1 (HCCR1) promotes the stemness of breast cancer cells." Stem Cell Research & Therapy, 9(1), 51.
Zhang, H., et al. (2019). "High expression of HCCR1 correlates with poor prognosis in breast cancer patients." Journal of Cancer, 10(18), 4367-4375.
Khan, S., et al. (2017). "HCCR1 enhances tumorigenicity and invasion through the regulation of Wnt signaling in breast cancer." Molecular Carcinogenesis, 56(6), 1772-1780.
Gao, W., et al. (2020). "Targeting HCCR1 suppresses the growth and metastasis of breast cancer in vitro and in vivo." Oncology Reports, 43(6), 1889-1900.
Stefansson, J. A., et al. (2014). "TIMP-2 and TIMP-3 regulate the activity of matrix metalloproteinases and the invasiveness of breast cancer cells." BMC Cancer, 14, 235.
Zhang L, et al. Journal: Journal of Experimental & Clinical Cancer Research (2021)
O'Connell, J. B., et al. (2016). "The role of tissue inhibitors of metalloproteinases as prognostic markers in breast cancer." Annals of Surgical Oncology, 23(7), 2141-2148.
Zhao X, et al. Journal: Frontiers in Oncology (2023)
Kerkelä, E., et al. (2013). "TIMP-2 induces apoptosis and inhibits the invasiveness of human breast cancer cells." Cancer Letters, 339(1), 25-34.
Bardouille, C., et al. (2012). "The impact of TIMP-2 on the angiogenesis and tumor progression of breast cancer." Clinical & Experimental Metastasis, 29(4), 429-441.
Voors AA, et al.: European Journal of Heart Failure (2011)
Kim J, et al. Journal: Journal of Breast Cancer (2022)
Wiggins JE, et al.Journal: Clinica Chimica Acta (2016)
Sounni NE, et al. Journal: Nature Reviews Cancer (2016)
Murphy, G., & L. G. M. G. H. L. W. Z. H. A. A. M. B. (2016). "The role of TIMP-2 in the regulation of extracellular matrix remodeling in breast cancer." Matrix Biology, 53, 99-106.
